Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India.
COVID-19
cancer
non-cancer
outcomes
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
12
09
2021
received:
01
09
2021
accepted:
23
09
2021
pubmed:
18
11
2021
medline:
4
1
2022
entrez:
17
11
2021
Statut:
ppublish
Résumé
There is paucity of data regarding clinical characteristics, laboratory parameters and outcomes of coronavirus disease (COVID-19) in cancer versus non-cancer patients, particularly from India. This was an observational, single-centre, retrospective analysis of patients with laboratory-confirmed COVID-19 hospitalised in our institution between 22 May 2020 and 1 December 2020. We compared baseline clinical characteristics, laboratory parameters and outcomes of COVID-19 (overall mortality, time to discharge) between cancer and non-cancer patients. A total of 200 COVID-19 infection episodes were analysed of which 109 (54.5%) were patients with cancer and 91 (45.5%) were patients without cancer. The median age was 43 (interquartile range [IQR]:32-57), 51 (IQR: 33-62) and 38 (IQR: 31.5-49.3) years; of whole cohort, cancer and non-cancer patients, respectively. Comparison of outcomes showed that oxygen requirement (31.2% [95% CI: 22.6-40.7] vs. 17.6% [95% CI: 10.4-26.9]; p = 0.03), median time to discharge (11 days [IQR: 6.75-16] vs. 6 days [IQR: 3-9.75]; p < 0.001) and mortality (10.0% [95% CI: 5.2-17.3] vs. 1.1% [95% CI: 0.03-5.9]; p = 0.017) were significantly higher in patients with cancer. In univariable analysis, factors associated with higher mortality in the whole cohort included diagnosis of cancer (10.1% vs. 1.1%; p = 0.027; odds ratio [OR]: 7.04), age ≥60 (17.4% vs. 2.6%; p = 0.001; OR: 7.38), oxygen requirement (22% vs. 0.6%; p < 0.001; OR: 29.01), chest infiltrates (19.2% vs. 1.4%; p < 0.001; OR: 22.65), baseline absolute lymphocyte count <1 × 10 Cancer patients with COVID-19 have higher mortality and require longer hospital stay. High procalcitonin levels and oxygen requirement during admission are other factors that affect outcomes adversely.
Sections du résumé
BACKGROUND
There is paucity of data regarding clinical characteristics, laboratory parameters and outcomes of coronavirus disease (COVID-19) in cancer versus non-cancer patients, particularly from India.
MATERIALS AND METHODS
This was an observational, single-centre, retrospective analysis of patients with laboratory-confirmed COVID-19 hospitalised in our institution between 22 May 2020 and 1 December 2020. We compared baseline clinical characteristics, laboratory parameters and outcomes of COVID-19 (overall mortality, time to discharge) between cancer and non-cancer patients.
RESULTS
A total of 200 COVID-19 infection episodes were analysed of which 109 (54.5%) were patients with cancer and 91 (45.5%) were patients without cancer. The median age was 43 (interquartile range [IQR]:32-57), 51 (IQR: 33-62) and 38 (IQR: 31.5-49.3) years; of whole cohort, cancer and non-cancer patients, respectively. Comparison of outcomes showed that oxygen requirement (31.2% [95% CI: 22.6-40.7] vs. 17.6% [95% CI: 10.4-26.9]; p = 0.03), median time to discharge (11 days [IQR: 6.75-16] vs. 6 days [IQR: 3-9.75]; p < 0.001) and mortality (10.0% [95% CI: 5.2-17.3] vs. 1.1% [95% CI: 0.03-5.9]; p = 0.017) were significantly higher in patients with cancer. In univariable analysis, factors associated with higher mortality in the whole cohort included diagnosis of cancer (10.1% vs. 1.1%; p = 0.027; odds ratio [OR]: 7.04), age ≥60 (17.4% vs. 2.6%; p = 0.001; OR: 7.38), oxygen requirement (22% vs. 0.6%; p < 0.001; OR: 29.01), chest infiltrates (19.2% vs. 1.4%; p < 0.001; OR: 22.65), baseline absolute lymphocyte count <1 × 10
CONCLUSION
Cancer patients with COVID-19 have higher mortality and require longer hospital stay. High procalcitonin levels and oxygen requirement during admission are other factors that affect outcomes adversely.
Identifiants
pubmed: 34786866
doi: 10.1002/cam4.4379
pmc: PMC8646792
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8777-8788Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Lancet. 2020 May 30;395(10238):1695-1704
pubmed: 32401715
JCO Glob Oncol. 2020 Jun;6:799-808
pubmed: 32511066
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
JAMA. 2020 Oct 6;324(13):1307-1316
pubmed: 32876695
JCO Glob Oncol. 2021 Jan;7:46-55
pubmed: 33434066
N Engl J Med. 2020 Nov 5;383(19):1827-1837
pubmed: 32459919
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Int Immunopharmacol. 2020 Dec;89(Pt A):107018
pubmed: 33045577
Ann Hematol. 2021 Feb;100(2):383-393
pubmed: 33159569
J Med Virol. 2020 Oct;92(10):2067-2073
pubmed: 32369209
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
J Clin Oncol. 2020 Nov 20;38(33):3914-3924
pubmed: 32986528
PeerJ. 2021 Jan 21;9:e10599
pubmed: 33552716
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Eur J Cancer. 2020 Nov;139:70-80
pubmed: 32977223
J Intern Med. 2020 Aug;288(2):192-206
pubmed: 32348588
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
Pediatr Hematol Oncol. 2021 Mar;38(2):161-167
pubmed: 33150828
Cancer Med. 2021 Dec;10(24):8777-8788
pubmed: 34786866
Indian J Med Res. 2020 Jul & Aug;152(1 & 2):61-69
pubmed: 32773414
Cancer Med. 2020 Dec;9(23):8747-8753
pubmed: 33128509
Blood Cells Mol Dis. 2021 Mar;87:102525
pubmed: 33338697
Cancer Med. 2020 Nov;9(22):8412-8422
pubmed: 32931637